乳腺癌肺转移机制及治疗进展

doi:10.11904/j.issn.1002-3070.2022.02.013

摘要/Abstract

摘要： 肺部是晚期乳腺癌的常见转移部位,肺转移可能引起咳嗽、咯血、疼痛、胸腔积液和肺功能障碍等临床症状,严重影响患者的生活质量。目前关于乳腺癌肺转移治疗有局部治疗和全身治疗,但是存在肺转移的乳腺癌患者的生存率仍然很低,提高患者的疗效和延长生存时间一直是患者及医务工作者关心的热点问题。本文将对乳腺癌肺转移机制及肺转移最新治疗进展进行综述,以期为乳腺癌肺转移患者临床治疗提供新思路。

关键词: 乳腺癌, 肺转移, 全身治疗, 局部治疗, 转移性乳腺癌

Abstract: Lung is a common metastatic site of advanced breast cancer.Lung metastasis may cause cough,hemoptysis,pain,pleural effusion and pulmonary dysfunction and other clinical symptoms,which seriously affect the life quality of patients.At present,there are local and systemic treatments for breast cancer lung metastasis,but the survival rate of breast cancer patients with lung metastasis is still very low.Improving the efficacy of patients and prolonging the survival time have been hot issues of concern to patients and medical workers.This paper briefly reviews the mechanism of breast cancer lung metastasis and the latest treatment progress of lung metastasis,in order to provide new ideas for the clinical treatment of breast cancer patients with lung metastasis.

Key words: Breast cancer, Lung metastasis, Systemic therapy, Local therapy, Metastatic breast cancer

中图分类号:

R737.9

孙元元, 张苧之, 曹孟儒. 乳腺癌肺转移机制及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(2): 173-177.

SUN Yuanyuan, ZHANG Ningzhi, CAO Mengru. The mechanism and treatment progress of breast cancer lung metastasis[J]. Journal of Practical Oncology, 2022, 36(2): 173-177.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.02.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I2/173

参考文献

1 Wu Q,Li JJ,Zhu S,et al.Breast cancer subtypes predict the preferential site of distant metastases:a seer based study[J].Oncotarget,2017,8(17):27990-27996.
2 Xiao W,Zheng S,Liu P,et al.Risk factors and survival outcomes in patients with breast cancer and lung metastasis:a population based study[J].Cancer Med,2018,7(3):992-930.
3 Ranran L,Yana Q,Man J,et al.Primary tumor secreted VEGF induces vascular hyperpermeability in premetastatic lung via the occludin phosphorylation/ubiquitination pathway[J].Mol Carcinogen,2019,58(12):2316-2326.
4 Braeden M,Alison L,Allan.Molecular mechanisms of breast cancer metastasis to the lung:clinical and experimental perspectives[J].Int J Mol Sci,2019,20(9):2272-2288.
5 Liao TT,Yang MH.Hybrid epithelial/mesenchymal state in cancer metastasis:clinical significance and regulatory mechanisms[J].Cells,2020,9(3):623-635.
6 Liang Y,Zhang H,Song X,et al.Metastatic heterogeneity of breast cancer:molecular mechanism and potential therapeutic targets[J].Semin Cancer Biol,2020,60:14-27.
7 Yousefi M,Nosrati R,Salmaninejad A,et al.Organ-specific metastasis of breast cancer:molecular and cellular mechanisms underlying lung metastasis[J].Cell Oncol,2018,41(2):123-140.
8 Li R,Qi Y,Han M,et al.Computed tomography reveals microenvironment changes in premetastatic lung[J].Eur Radiol,2020,11(21):1-10.
9 Ye Q,Han XW,Wu ZS.Bioinformatics analysis to screen key prognostic genes in the breast cancer tumor microenvironment[J].Bioengineered,2020,11(1):1280-1300.
10 Urooj T,Wasim B,Mushtaq S,et al.Cancer cell-derived secretory factors in breast cancer-associated lung metastasis:their mechanism and future prospects[J].Curr Cancer Drug Tar,2020,20(3):168-186.
11 Xiao YS,Cong M,Li JT,et al.Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation[J].Cancer Cell,2021,21(3):423-437.
12 Petrella F,Diotti C,Rimessi A,et al.Pulmonary metastasectomy:an overview[J].Thorac Dis,2017,9(12):1291-1298.
13 Macherey S,Mallmann P,Malter W,et al.Lung metastasectomy for pulmonary metastatic breast carcinoma[J].Geburtshilfe Frauenheilkd,2017,77(6):645-650.
14 Endoh M,Shiono S,Yamauchi Y,et al.Pulmonary metastasectomy for pulmonary metastasis of breast cancer has a limited prognostic impact:a multi-institutional retrospective analysis[J].J Thorac Dis,2020,12(11):6552-6562.
15 Bolca C,Jentimir I,Fotache G,et al.Pulmonary metastasectomy-general issues[J].Pneumol,2015,64(2):20-22.
16 Dackam S,Ojanguren A,Perentes JY,et al.Pulmonary metastasectomy[J].Rev Med Suisse,2019,15(655):1221-1225.
17 Hassan M,Graeter T,Haager B,et al.A prospective bicentric study to evaluate surgical outcome and lung function changes after laser-assisted pulmonary metastasectomy[J].Zbl Chir,2019,144(1):64-76.
18 Sponholz S,Baldes N,Schirren M,et al.Sternal resection for breast cancer metastases[J].Thorac Cardiovasc Surg,2018,66(2):164-169.
19 Li X,Huang R,Ma L,et al.Locoregional surgical treatment improves the prognosis in primary metastatic breast cancer patients with a single distant metastasis except for brain metastasis[J].Breast,2019,45(3):104-112.
20 Chen Y,Li Q,Zhang P,et al.58P survival benefit of local treatments in breast cancer with lung metastasis:results from a large retrospective study-science direct[J].Ann Oncol,2020,31(6):1264-1265.
21 Marta S,Davide F,Fiorenza DR,et al.Stereotactic body radiation therapy:a promising chance for oligometastatic breast cancer[J].Breast J,2016,26(3):11-17.
22 Oura S,Mori M,Makimoto S.A case of solitary lung metastasis of breast cancer successfully treated with stereotactic body radiotherapy after chemotherapy[J].Case Rep Oncol,2020,13(1):398-402.
23 Anthony R,Joanne D,William R,et al.Lung metastases treated with stereotactic body radiotherapy:the rssearch patient registry′s experience[J].Radiat Oncol,2017,12(1):35-42.
24 Ashok K,Hari M,Sharad B,et al.Radiation for palliation:role of palliative radiotherapy in allevieating pain/symptoms in a prospective observational study at two tertiary care centers[J].IJPC,2019,25(3):391-397.
25 Taylor C,Correa C,Duane FK,et al.Estimating the risks of breast cancer radiotherapy:evidence from modern radiation doses to the lungs and heart and from previous randomized trials[J].J Clin Oncol,2017,35(15):1641-1649.
26 Zhu Q,Kirova YM,Cao L,et al.Cardiotoxicity associated with radiotherapy in breast cancer:a question-based review with current literatures[J].Cancer Treat Rev,2018,68(3):9-15.
27 Yuan TZ,Zhan ZJ,Qian CN.New frontiers in proton therapy:applications in cancers[J].Cancer Commun,2019,39(1):61-67.
28 Barth RF,Mi P,Yang W.Boron delivery agents for neutron capture therapy of cancer[J].Cancer Commun,2018,38(1):1-15.
29 Li LP,Dai K,Li JY,et al.A boron-10 nitride nanosheet for combinational boron neutron capture therapy and chemotherapy of tumor[J].Biomaterials,2021,1(268):120587-120609.
30 García TA,Guma A,Soler T,et al.Radiofrequency ablation followed by surgical excision versus lumpectomy for early stage breast cancer:a randomized phase II clinical trial[J].Radiology,2018,289(2):317-324.
31 Ito T,Oura S,Nagamine S,et al.Radiofrequency ablation of breast cancer:a retrospective study[J].Clin Breast Cancer,2017,4(18):495-500.
32 Li J,Wang DD,Zhao YN,et al.Clinical assessment of magnetic resonance imaging-guided radiofrequency ablation for breast cancer[J].Mol Clin Oncol,2019,11(4):411-415.
33 Kazmi S,Chatterjee D,Raju D,et al.Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin,gemcitabine,or capecitabine[J].Breast Cancer Restr,2020,184(2):559-565.
34 Baiomy MA,Kashef WF.ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy[J].APJCP,2017,18(2):507-513.
35 Zhou Y,Jing LI,Peng SJ.The effect of lapatinib targeting therapy on the expression of tumor markers in breast cancer lung metastasis patients with HER2 positive[J].Labeled Immunoassays Clin Med,2018,25(7):1021-1024.
36 Waks AG,Winer EP.Breast cancer treatment:a review[J].JAMA,2019,321(3):288-300.
37 Goto W,Kashiwagi S,Takada K,et al.A case of multiple lung metastases from breast cancer successfully treated with endocrine therapy[J].Gan To Kagaku Ryoho,2018,45(13):2426-2428.
38 Ozawa H,Sata A,Fukui R,et al.A single-centre,retrospective,observational analysis of fulvestrant for recurrent metastatic breast cancer according to metastatic site[J].Anticancer Res,2019,39(10):5653-5662.
39 He M,Li JJ,Zuo WJ,et al.Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant[J].Cancer Med,2019,8(14):6212-6220.
40 王晶晶,贾彦焘.麦门冬汤合参蛤散加减治疗乳腺癌肺转移验案举隅[J].中国现代医药杂志,2020,22(1):79-80.
41 范洪桥,周亮,王月,等.刘丽芳教授从“气化”理论论治乳腺癌肺转移经验[J].中医药学报,2020,48(8):37-40.
42 Stefano G,Karl A,Odisseas Z,et al.Isolated thoracic perfusion in lung metastases from breast cancer:a retrospective observational study[J].Updates Surg,2019,71(1):165-177.
43 Dai PC,Nguyen HT,Tran TTP,et al.Combined hyperthermia and chemotherapy as a synergistic anticancer treatment[J].J Pharm Investig,2019,49(5):519-526.
44 Sawai H,Kurimoto M,Suzuki Y,et al.Efficacy of hyperthermia in treatment of recurrent metastatic breast cancer after long-term chemotherapy:a report of 2 cases[J].AJCR,2020,21(3):926647-926656.
45 Ridouani F,Solomon SB,Bryce Y,et al.Predictors of progression free survival and local tumor control after percutaneous thermal ablation of oligometastatic breast cancer:retrospective study[J].J Vasc Intervl Radio,2020,31(8):1201-1209.

[1]	侯建勋, 王洪斌. 外泌体对乳腺癌诊疗一体化影响的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 178-182.
[2]	陈赫, 王秋程, 程文. 自动乳腺超声诊断系统在乳腺癌方面的应用进展[J]. 实用肿瘤学杂志, 2022, 36(2): 193-196.
[3]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[4]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[5]	罗波, 张曲, 郑红梅, 梁新军, 周小妹, 吴新红. SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J]. 实用肿瘤学杂志, 2021, 35(6): 523-528.
[6]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.
[7]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[8]	周天虹, 顾秀瑛, 姚芳, 宋述铭. 乌鲁木齐市2014—2018年度乳腺癌筛查结果分析[J]. 实用肿瘤学杂志, 2021, 35(5): 391-395.
[9]	马补换, 刘彩霞. Jagged1促进乳腺癌发生发展及远处转移的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 452-457.
[10]	秦朝, 李江, 郑亚迪, 王飞, 曹巍, 许永杰, 余一雯, 赵亮, 于欣阳, 陈宏达, 任建松, 王勇, 李静, 李霓, 陈万青. 中国城市乳腺癌高危人群筛查依从性及其相关因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 291-296.
[11]	郭兰伟, 张韶凯, 刘曙正, 郑黎阳, 陈琼, 曹小琴, 孙喜斌, 张建功. 河南省城市地区乳腺癌筛查依从性及其影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 307-313.
[12]	李钰莹, 张悦. Sirtuins在乳腺癌中作用机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 277-281.
[13]	提谦, 张清媛. CDK4/6抑制剂联合内分泌治疗晚期乳腺癌[J]. 实用肿瘤学杂志, 2021, 35(3): 287-290.
[14]	杨敏, 张娇燕, 段丹, 徐兵河. 乳腺癌照顾者研究的文献计量学及可视化分析[J]. 实用肿瘤学杂志, 2021, 35(2): 110-116.
[15]	王健宇, 张显玉, 庞达. Luminal A型乳腺癌新辅助化疗疗效的影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(2): 131-136.